Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma
Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. Journal of Clinical Oncology. 34:4102-4109.